MICONAZOLE 3 COMBINATION PACK
Clinical safety rating: safe
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and fungal cell death.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways involving cytochrome P450 enzymes, particularly CYP3A4. It is excreted mainly as inactive metabolites in bile and feces, with less than 1% excreted unchanged in urine. |
| Excretion | Renal: approximately 10-20% as unchanged drug; fecal: >50% as metabolites; biliary: minor route. The majority is eliminated via feces as metabolites, reflecting hepatic metabolism and biliary excretion. |
| Half-life | Terminal elimination half-life is 20-25 hours (intravaginal administration). This long half-life supports a 3-day dosing regimen, maintaining therapeutic concentrations. |
| Protein binding | Approximately 88-93% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 1.4 L/kg, indicating extensive tissue distribution including vaginal mucosa. This supports local and systemic penetration after topical application. |
| Bioavailability | Intravaginal: minimal systemic absorption (~1-2% of dose); oral: ~25-30% but not used systemically due to poor bioavailability and rapid metabolism. |
| Onset of Action | Intravaginal: relief of symptoms (itching, discharge) begins within 24-72 hours. Clinical improvement noted after first dose, but full effect typically by day 3. |
| Duration of Action | Duration of antifungal effect is approximately 72 hours after last dose, with continued suppression of Candida species. Cure usually achieved with 3-day regimen; residual benefits may last 1-3 days post-treatment. |
Intravaginal: 1 applicatorful (100 mg) at bedtime for 3 consecutive nights.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children ≥12 years: Same as adult dosing. Children <12 years: Safety and efficacy not established. |
| Geriatric use | Same as adult dosing; no specific adjustment needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
| FDA category | Human |
| Breastfeeding | Excretion into human milk unknown after vaginal use; minimal systemic absorption suggests low risk. M/P ratio not established. Use caution, especially in nursing infants with hepatic impairment. |
| Teratogenic Risk | Pregnancy Category C. Limited human data; no evidence of teratogenicity in animal studies at systemic exposures similar to human doses. Vaginal absorption is minimal; first trimester use generally avoided unless benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Common Effects | vaginal yeast infections |
| Serious Effects |
Hypersensitivity to miconazole or any component of the formulation. Do not use for fungal infections of the nails or scalp. Avoid in patients with known hepatic impairment (for systemic use). Topical use contraindicated in patients with known hypersensitivity to peanut or soya (if formulation contains these excipients).
| Precautions | Hepatic impairment may require dose adjustment. Caution in patients with known hypersensitivity to azole antifungals. Risk of allergic reactions including anaphylaxis. Potential for skin irritation at application site. Not for ophthalmic or oral use (except as directed). Avoid concurrent use with other azole antifungals that may increase systemic absorption. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required. Routine prenatal care suffices. For prolonged therapy, assess liver function tests periodically. |
| Fertility Effects | No known effects on fertility. Animal studies show no impairment at systemic levels. |